GALT
Galectin Therapeutics Inc.
4.39
1 x 3.19
1 x 5.60
bid
ask
+
0.06
1.39%
09:51 AM
timesize
Ytd5.53%
1y102.30%
4.36
day range
4.43
2.03
52 week range
7.13
Open4.38Prev Close4.33Low4.36High4.43Mkt Cap289.77M
Vol26.42KAvg Vol583.87KEPS-0.41P/EN/AForward P/E-0.53
Beta0.63Short Ratio42.37Inst. Own15.77%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1550-d Avg2.67200-d Avg3.711yr Est11.00

GALT News

Top 3 Health Care Stocks That May Keep You Up At Night In June
benzinga.com
Top 3 Health Care Stocks That May Keep You Up At Night In June

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,

Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
seekingalpha.com
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside

Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and c

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
zacks.com
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosi

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

benzinga.com
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) wit

benzinga.com
Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For

Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies f

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
globenewswire.com
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with

NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotec

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis
globenewswire.com
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Pot

NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which missed the

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
globenewswire.com
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the lead

benzinga.com
Galectin Therapeutics Announces Publication Of Results From NAVIGATE Phase 2b Clinical Trial Evaluat

Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeu

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
globenewswire.com
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the

NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), a clinica

Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
globenewswire.com
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics,

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism

benzinga.com
Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the an

Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)
defenseworld.net
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get

Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX)
defenseworld.net
Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX)

Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get

Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript
seekingalpha.com
Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirr

Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirr

benzinga.com
Galectin Therapeutics To Host Virtual KOL Event On March 10, Focusing On Unmet Need And Current Trea

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeuti

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud
newsfilecorp.com
Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potenti

New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that i

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeuti

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors
newsfilecorp.com
Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that i

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeuti

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeuti

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm
globenewswire.com
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Scha

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights li

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeuti

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com
HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11

HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.

benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) wit

benzinga.com
Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the an

benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com
HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6

HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with

benzinga.com
Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the an

benzinga.com
Galectin Therapeutics Issues Presentation Highlighting Its Focused Pipeline, MASH Cirrhosis And Onco

https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18

benzinga.com
HC Wainwright & Co. Reiterates Neutral on Galectin Therapeuticsto Neutral

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) from Neutr

benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com
Dow Surges Over 600 Points, Gold Jumps 1.5%

benzinga.com
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

benzinga.com
Dow Surges 100 Points, Carnival Earnings Top Views